Shionogi CEO says firm is pursuing acquisitions and mulling expanded U.S. production
The pharmaceutical manufacturer wants to accelerate its overseas growth while broadening its portfolio beyond its traditional strength in infectious disease medications.
Shionogi, a Japanese pharmaceutical company, is actively seeking to expand its operations and reduce geopolitical risk through strategic acquisitions, according to the company's CEO, Isao Teshirogi. In an interview, Teshirogi revealed that the Osaka-based firm is actively pursuing at least three potential acquisitions, with targets in the U.S., Japan, and Europe.
These acquisitions would focus on companies specializing in infectious and rare diseases. Teshirogi emphasized that the company's robust financial position makes it "absolutely no hesitation" to pursue M&A deals. This move is aimed at diversifying Shionogi's production base and mitigating risks associated with geopolitical factors over the next decade.
Written by urgent.news from Japan Times's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
